Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-label, Randomized, Parallel-group, Single Dose Study to Assess the Relative Bioavailability of a New BMS-986419 Immediate-release Tablet Formulation Compared to a Reference Enteric Capsule (Delayed-release) Formulation, and to Assess the Effect of Food on the Pharmacokinetics of Immediate-release Tablet Formulation in Healthy Adult Participants
Conditions
Interventions
BMS-986419 DR Capsule
BMS-986419 IR Tablet
Locations
1
United States
Anaheim Clinical Trials
Anaheim, California, United States
Start Date
August 8, 2023
Primary Completion Date
October 17, 2023
Completion Date
October 17, 2023
Last Updated
January 23, 2024
NCT00104325
NCT07118891
NCT01399385
NCT07295717
NCT03807401
NCT07271693
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions